生物标志物在帕金森病脑深部电刺激中的应用综述:成功的过去预示光明的未来
该综述按PRISMA指南系统检索PubMed(1952年至今),初检获49篇,30篇符合纳入标准,分为已证实临床实用性的生物标志物和具有未来应用潜力的生物标志物。局部场电位和β频段分析是帕金森病脑深部电刺激临床公认的首选生物标志物,未来研究需确定哪些生理变化最适合用作生物标志物及其最适用的情境。
要点
- 局部场电位和β频段分析是帕金森病脑深部电刺激临床公认的首选生物标志物。
- 脑深部电刺激后中枢神经系统在电生理振荡、基因表达、神经肽水平、代谢功能、炎症活动等方面存在可测量的差异。
- 未来研究需确定哪些已注意到的生理变化最适合用作生物标志物及其最适用的情境。
核心结论
- 已识别出有助于判断脑深部电刺激对帕金森病患者效果的生物标志物,局部场电位和β频段分析是临床公认的首选生物标志物。
- 所识别出的许多变化可作为临床有用的生物标志物用于监测脑深部电刺激,未来研究需确定哪些生理变化最适合用作生物标志物及其最适用的情境。
研究设计与样本
- 该研究为综述,按PRISMA系统评价指南系统检索PubMed数据库,纳入评估脑深部电刺激后可测量的当前或潜在生物标志物的研究,检索文章时间范围为1952年至今。
- 初检识别49篇文章,30篇符合纳入标准,文章分为已证实临床实用性的生物标志物和具有未来应用潜力的生物标志物两类。
主要发现
- 当前研究显示,帕金森病患者脑深部电刺激后中枢神经系统在电生理振荡、基因表达、神经肽水平、代谢功能、炎症活动等方面存在可测量的差异。
- 局部场电位和β频段分析是帕金森病脑深部电刺激临床公认的首选生物标志物。
- 所识别出的许多变化可作为临床有用的生物标志物用于监测脑深部电刺激。
临床怎么用
- 作者认为,所识别出的许多变化可作为临床有用的生物标志物用于监测脑深部电刺激。
- 作者认为,未来研究需确定哪些已注意到的生理变化最适合用作生物标志物及其最适用的情境。
局限性
- 作者指出未来研究需确定哪些已注意到的生理变化最适合用作生物标志物及其最适用的情境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Parkinson disease (PD) remains a common neurodegenerative disorder. Functional neurosurgery largely arose with the introduction of deep brain stimulation (DBS) as a potential option for PD unresponsive to medical management. Biomarkers are clinical and laboratory indicators of therapeutic success or failure. OBJECTIVE: To examine the current and published literature relating to the development and use of biomarkers in monitoring and determining the efficacy of DBS in PD. METHODS: The PubMed database was systematically searched using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for systemic reviews. Studies that examined current or potential biomarkers measurable after DBS were included. Articles from 1952 to date were examined. RESULTS: The initial search identified 49 articles. Thirty articles met the inclusion criteria. Articles were subdivided into those addressing biomarkers with proven clinical usefulness and potential biomarkers that have future application. CONCLUSIONS: Biomarkers have been identified that can help to determine the effect of DBS on patients with PD. Current studies show that there are measured differences in electrophysiologic oscillations, gene expression, neuropeptide levels, metabolic function, inflammatory activity, and others in the central nervous system after DBS in PD. Local field potential and β-band analysis stand as the clinically proven biomarkers of choice for DBS in PD. Many of the identified changes noted could be implemented as clinically useful biomarkers through which DBS may be monitored. Future studies are needed to determine which noted physiologic changes are most appropriately used as biomarkers and in which contexts they are most helpful.
引用
- Mugge L, Krafcik B, Pontasch G, et al. A Review of Biomarkers Use in Parkinson with Deep Brain Stimulation: A Successful Past Promising a Bright Future. World Neurosurg. 2018. PMID: 30576816. doi:10.1016/j.wneu.2018.11.247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。